Establishing the Minimal Clinically Important Difference (MCID) for Smartphone-Derived Gait Measures in Multiple Sclerosis

Introduction to the show: ident: Genomics Radio. Generated commentary on the latest computational biology and genomics papers.

Ines: Hi, I'm Ines.

Marcus: And I'm Marcus, here with Yuki.

Ines: We're looking at the paper: "Establishing the Minimal Clinically Important Difference (MCID) for Smartphone-Derived Gait Measures in Multiple Sclerosis".

Marcus: Here's the gist of the paper. The gist The study establishes robust and clinically meaningful MCIDs for smartphone-derived digital gait measures in progressive MS, providing a framework for interpreting remote monitoring data.

Ines: Digital health technologies allow for frequent, remote gait monitoring in people with multiple sclerosis (MS) but established minimal clinically important differences (MCID) are required to differentiate daily variability from actual disease progression in longitudinal data <ref:2606.28449#pg2> Gait impairments are among the most prevalent and impactful manifestations of MS, affecting patients’ quality of life, functional independence, and overall well-being <ref:2606.28449#pg4> Advances in digital health technologies, particularly the use of smartphone-based inertial measurement units (IMUs), have enabled the collection of continuous and high-resolution gait data in both clinical and real-world settings <ref:2606.28449#pg6> Gait measures, such as total distance walked and spatiotemporal measures like step velocity, step duration, and step length derived from smartphone IMUs during remote walking tests offer a promising complement to traditional clinical assessments <ref:2606.28449#pg8> However, for these digital gait measures to be interpretable and actionable, it is critical to understand what constitutes a clinically meaningful change <ref:2606.28449#pg9> The minimal clinically important difference (MCID) is the most common approach, and it represents the smallest within-patient change in an outcome measure that is meaningful to patients, reflecting a tangible improvement or worsening in their daily lives <ref:2606.28449#pg10> Currently, there is limited published evidence on MCID values for digital gait measures, which limits their integration into medical research and clinical decision-making To address this gap, we estimated MCIDs for smartphone-based digital gait measures using an anchorbased method that included multiple clinician-administered and patient-reported outcomes The analyses were conducted in a prospective cohort of patients with progressive MS enrolled into the CONSONANCE (NCT03523858) study over 2 years Additionally, this work was supplemented with qualitative results to ensure these digital gait measures are meaningful and relevant to patients.

Marcus: The researchers utilized a phase 3b study of ocrelizumab in progressive MS, CONSONANCE (NCT03523858), where participants underwent daily, unsupervised, smartphone-based Two-Minute Walk Test (2MWT) <ref:2606.28449#pg10> Digital gait measures derived from the 2MWT include those assessing the quality of gait and those assessing the quantity of gait.

Ines: Multiple anchors were administered during study visits, including performance-based measures (Timed 25-Foot Walk

T25FW: ), clinician-rated measures (EDSS and its Ambulation Score subcomponent), and patient-reported outcome measures (12-item Multiple Sclerosis Walking Scale

MSWS-12: ) <ref:2606.28449#pg9> Additional anchors included patient-reported outcomes on lower-limb specific symptoms (Patient Impression of Severity for Lower Limbs

PSI [Lower Limbs: ]), disease severity (Patient Global Impression of Severity

PGI-S: ), and change in disease severity (Patient Global Impression of Change

PGI-C: ).

Paper summary: Ines: So to recap, this paper "Establishing the Minimal Clinically Important Difference (MCID) for Smartphone-Derived Gait Measures in Multiple Sclerosis" is focused on creating a set of robust and clinically meaningful thresholds for interpreting remote gait monitoring data in MS patients.

Marcus: The main point they’re making is that without these established MCIDs, it's hard to separate normal daily variability from actual disease progression when looking at longitudinal data from digital gait metrics.

Yuki: It claims that they used an anchor-based method by computing median changes from baseline at Week ninety-six on those digital gait measures for patients who showed clinically meaningful worsening on things like the Timed twenty-five-Foot Walk or the Ambulation Score <ref:2606.28449#pg2,median changes from baseline at Week 96 on>.

Ines: They then triangulated these median changes to derive MCID estimates, specifically proposing values for Step Velocity, Step Duration, Step Length, and Total Number of Steps.

Marcus: The results they found were specific numbers: -zero point one six m/s for Step Velocity and-twenty-four meters for Total Distance Walked as the minimal changes they determined across all their anchors.

Yuki: These MCIDs are presented as a framework to help interpret meaningful gait changes and integrate these digital measures into MS outcome evaluation, which is something that has been missing in the literature before.

Ines: So essentially, they provide a concrete set of benchmarks for interpreting smartphone-derived gait data in progressive MS patients.

Marcus: They found two hundred forty-three patients with progressive MS had this data available, and their study included female participants making up fifty-one percent of that group <ref:2606.28449#pg2,243 patients with progressive MS>.

Yuki: It’s helpful to know the sample size and demographics when you’re trying to see if a set of metrics is representative enough for broader application in population genetics or clinical trials.

Ines: The paper also mentions that correlations between walking impairment perceived by patients and the digital gait measures were quite strong, with the MSWS-twelve showing the strongest correlation <ref:2606.28449#pg2>.

Marcus: That's significant because it links what a patient *feels* about their walking directly to what their smartphone is measuring, which validates its usefulness.

Yuki: It supports the idea that these digital metrics are relevant because patients actually report symptoms that relate directly to gait performance and daily activities.

Conclusion: Ines: So, looking at the title "Establishing the Minimal Clinically Important Difference (MCID) for Smartphone-Derived Gait Measures in Multiple Sclerosis" and the authors—Mike D Rinderknecht, Bernhard Fehlmann, Dimitar Stanev, Cedric Simillion, Ernst Bos, Letizia Leocani and Agne Kazlauskaite—it's clear they are focusing on creating a standardized tool for interpreting this type of data.

Marcus: They’ve taken something that used to be just raw smartphone movement numbers and turned it into a clinically actionable framework by providing these specific MCID estimates.

Yuki: What this means in simple terms is that clinicians can now use these thresholds to look at someone's weekly gait data and determine if they are seeing a significant change in their MS disease progression, rather than just noise.

Ines: It gives us a way to objectively monitor disease activity in real-world settings, which is crucial for both evaluating new treatments in clinical trials and for providing objective insights into personalized patient care.

Marcus: They’ve laid the groundwork for using these digital gait measures to evaluate treatment efficacy beyond just traditional clinical endpoints.

Yuki: It's a framework that allows us to use objective, real-world monitoring to advance personalized patient care by setting clear thresholds for what counts as meaningful progression in MS.